Q-Line Biotech IPO
Bookbuilding IPO | ₹214.00 Cr | Listing at NSE SME
Closed
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Price Band
₹326.00 to ₹343.00
Market Cap (Pre-IPO)
-
IPO Details
| IPO Date | May 21, 2026 to May 25, 2026 |
| Listing Date | Tentative: May 29, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹326.00 to ₹343.00 |
| Lot Size | 400 Shares (Minimum: ₹137,200.00) |
| Sale Type | Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Issue Size | ₹214.00 Crores |
| Total Shares Offered | 6,253,200 shares |
| Fresh Issue | 5,940,000 shares |
| Offer For Sale | 6,253,200 shares |
Q-Line Biotech IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 29,69,200 |
| Retail Shares Offered | 20,79,200 |
| NII Shares Offered | 8,91,600 |
Q-Line Biotech IPO Lot Size
Investors can bid for a minimum of 800 shares and in multiples of 400 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 800 | ₹274,400 |
| Retail (Max) | 2 | 800 | ₹274,400 |
| S-HNI (Min) | 3 | 1,200 | ₹411,600 |
| S-HNI (Max) | 7 | 2,800 | ₹960,400 |
| B-HNI (Min) | 8 | 3,200 | ₹1,097,600 |
Q-Line Biotech Financial Information (Restated Consolidated)
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 21,288,920.00 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 17.66% |
| ROCE (Return on Capital Employed) | 23.74% |
| Debt/Equity | 0.87 |
| RoNW (Return on Net Worth) | 23.74% |
| PAT Margin (Profit After Tax Margin) | 8.97% |
| EBITDA Margin | 22.73% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 96.77% | - |
Company Promoters
- The promoters of the company are Saurabh Garg
- Amita Garg
- Ayush Garg
- Ajay Kumar Mahanty and Abhay Agrawal.
Company Overview
Q-Line Biotech – Company Overview
- Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the development, manufacturing, and marketing of diagnostic reagents, kits, consumables, and diagnostic equipment for healthcare applications.
Core Segments
- Reagents & Kits: Clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, rapid tests, and POC devices
- IVD Equipment: In-vitro diagnostic and pathology equipment supply/manufacturing
- Diagnostic Consumables: Products for hospitals, labs, and medical colleges
- The company supplies diagnostic equipment and IVD products directly and through distributors to diagnostic centers, hospitals, and medical institutions.
- Its manufacturing operations focus on indigenous production of diagnostic reagents and healthcare devices.
- As of December 31, 2025, the company had an annual production capacity of around 1.4 million diagnostic kits and 1,200 Selectra Machines.
- The company emphasizes research, quality manufacturing, and healthcare diagnostics solutions to support the medical industry.
- As of March 31, 2026, the manufacturing operations included 126 employees and 223 third-party workers.
Company Strengths
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Experienced Promoter and Management team
Use of Proceeds
| 1) | To meet working capital requirements | 93.50 |
| 2) | Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| 3) | General Corporate Purposes | |
| Total | 183.50 |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Quick Info
| Sector | Healthcare and Medical Equipment |
| Exchange | NSE SME |
Important Dates
| IPO Open | May 21, 2026 |
| IPO Close | May 25, 2026 |
| Allotment Date | May 26, 2026 |
| Credit to Demat | May 27, 2026 |
| Listing Date | Tentative: May 29, 2026 |
Lead Manager(s)
Hem Securities Ltd.
Registrar
Purva Sharegistry (India) Pvt.Ltd.
+91-022-23018261/ 23016761
Description
- IPO Type: Book build issue aggregating to ₹214.48 crores.
- Issue Structure: Entirely a fresh issue of 0.63 crore shares totaling ₹214.48 crores.
- IPO Dates: The issue opens on May 21, 2026 and closes on May 25, 2026.
- Allotment Date: Expected to be finalized on May 26, 2026.
- Listing Details: Shares are proposed to be listed on the SME platform of the National Stock Exchange of India (NSE SME) with a tentative listing date of May 29, 2026.
- Retail Investment Requirement: Minimum 2 lots (800 shares) amounting to approximately ₹2,74,400 (at upper price band).
- HNI Investment Requirement: Minimum 3 lots (1,200 shares) totaling around ₹4,11,600.
- IPO Price Band: ₹326 to ₹343 per equity share.
- Lot Size: 400 shares per lot.
This IPO offers investors an opportunity to participate in the biotechnology and healthcare sector, subject to market risks.